Abstract
Gene transfer holds promise as a therapeutic modality for the treatment of vascular and cardiovascular disease. Initial phase I trials have demonstrated that gene transfer is feasible and is relatively well tolerated in the short term with limited morbidity and no discernable increase in mortality. Important questions remain to be answered regarding the use of gene therapy for cardiovascular disease. Many of these must be addressed by randomized, double-blinded, multicenter clinical trials. Ultimately, the application of gene therapy to cardiovascular disease will depend on the demonstration of clinical outcomes that are superior to those achieved using the current standards of care.
Original language | English |
---|---|
Pages (from-to) | 181-188 |
Number of pages | 8 |
Journal | Annals of Vascular Surgery |
Volume | 14 |
Issue number | 2 |
DOIs | |
State | Published - 2000 |
Externally published | Yes |